American shoppers can now buy sunscreen with a genuinely new active ingredient for the first time in more than 25 years: bemotrizinol, a UV filter used in Europe and Asia for decades, began reaching US store shelves on October 14, 2026, following its FDA approval in June — closing a long-standing gap in American sun protection that dermatologists say has contributed to skin-cancer risk.
Illustration: A sunscreen bottle on a beach with a glowing UV shield, representing the breakthrough new sunscreen ingredient
What Happened
The first sunscreens containing bemotrizinol (BEMT) reached US store shelves during the week of October 14, 2026, according to Associated Press reporting cited by Orbit Post on October 15. The rollout follows the Food and Drug Administration's June 2026 decision to clear the ingredient — the first new active sunscreen ingredient approved in the United States since the late 1990s, ending a drought of more than a quarter-century.
Bemotrizinol is not a new molecule. Sold to formulators under names including Tinosorb S and Parsol Shield, it has been a staple of European sunscreens since 2000 and is widely used across Asia. What is new is its American debut: for decades, US sunscreen makers were limited to a short list of aging filters approved in the 1990s, while their European counterparts formulated with newer, more effective ingredients.
The reason dermatologists are excited is not novelty alone. BEMT is an oil-soluble chemical filter that absorbs both UVA and UVB on its own — with absorption peaks near 310 nanometers in the UVB range and 340 nanometers in the UVA range — and it does so without the chalky white residue left by mineral filters like zinc oxide and titanium dioxide.
Illustration: A dermatologist applying sunscreen with a molecular UV barrier cross-section, showing advanced skin sun protection
On safety, the FDA deemed bemotrizinol generally recognized as safe and effective (GRASE) for adults and children 6 months and older, cleared at concentrations up to 6%. The agency's review drew on studies involving more than 500 patients that showed no irritation or allergic reactions, and on absorption data showing plasma levels rarely exceeded the FDA's 0.5 nanogram-per-milliliter threshold — attributed to the molecule's large size and low skin penetration, according to WebProNews' October 15 coverage.
The brand leading the American rollout is Ultra Violette, the first company selling a BEMT-containing sunscreen in the US, with a second formula scheduled for January 2027, Badiyaa reported on October 16. More brands are expected to launch BEMT formulas heading into summer 2027, as formulators race to incorporate the newly available filter.
Background
To understand why one ingredient matters so much, it helps to know how American sunscreen regulation works — and why it froze in time. In the US, sunscreens are regulated as over-the-counter drugs, not cosmetics. Adding a new active ingredient requires either a full new-drug application or a change to the FDA's sunscreen monograph, the rulebook listing approved filters. For decades, the monograph pathway was effectively stalled, leaving American consumers with roughly the same filters their parents used.
The breakthrough came through the CARES Act pathway, which gave the FDA a streamlined mechanism to update monographs. In June 2026 the agency finalized the addition of bemotrizinol to the OTC sunscreen monograph, with acting FDA director Mike Davis calling it "generally recognized as safe and effective for adults and children aged 6 months and older."
The molecule itself was developed in Switzerland in the 1990s. Its standout trait is standalone UVA coverage. The European Union requires sunscreens to provide UVA protection of at least one-third of the labeled SPF; the United States has no equivalent standard. That regulatory gap meant American "broad spectrum" products could legally offer far weaker UVA defense — and UVA is the wavelength most implicated in photoaging and a significant contributor to skin-cancer risk, since it penetrates deeper into the skin than UVB.
Stanford dermatologist Susan Swetter told The Plain Record in September that the UVA gap in American formulas was a genuine public-health shortfall, noting that regular sunscreen use from early life is associated with roughly 80% lower adult skin-cancer risk. Bemotrizinol's strong UVA absorption — peaking at 340 nm — directly addresses that weakness.
Why It Matters
First, this is a genuine consumer-health upgrade, not a marketing story. Skin cancer is the most commonly diagnosed cancer in the United States, and the UVA-protection gap in American sunscreens has been documented for years. A filter that delivers robust UVA coverage without a white cast removes the two biggest barriers — efficacy and wearability — that kept people under-protected.
Second, the approval cracks open a regulatory door that had been shut for a generation. The 25-plus-year gap since the last new filter was not for lack of science — several modern European filters have languished in the FDA's inbox for years. Bemotrizinol's successful passage through the monograph pathway creates a template that could, in principle, bring more of those filters to American shelves.
Illustration: The sun emitting UVA and UVB rays being absorbed by a molecular shield, an educational view of sun protection
Third, the commercial rollout is just beginning, which gives the story months of shelf life. Ultra Violette's January 2027 follow-up formula, plus the expected wave of BEMT launches ahead of summer 2027, means consumers will be encountering this ingredient — and dermatologists will be weighing whether to recommend it by name — well into next year. As one New York dermatologist quoted by AP noted, this is a molecule with decades of safety data abroad, not an untested new chemical.
What Happens Next
In the near term, expect a formulation race. With the monograph door now open and a proven filter available, major sunscreen brands are widely expected to announce BEMT-containing products through late 2026 and into the spring, ahead of the summer 2027 sun season. Ultra Violette's second formula in January 2027 will be an early indicator of how aggressively the market moves.
The bigger question is whether bemotrizinol is the first of several. Other modern filters long used in Europe remain in the FDA's queue, and the monograph precedent set in June 2026 gives their sponsors a clearer path.
Sponsored: explore today's featured sponsored offers
FAQ
What is bemotrizinol?
Bemotrizinol (BEMT), sold to formulators as Tinosorb S or Parsol Shield, is an oil-soluble chemical UV filter that absorbs both UVA and UVB. Developed in Switzerland in the 1990s and used in European sunscreens since 2000, it was FDA-approved for US use in June 2026.
Why is this the first new sunscreen ingredient in 25 years?
US sunscreens are regulated as over-the-counter drugs, and the FDA's approval pathway for new active ingredients was effectively stalled for decades. The CARES Act gave the agency a streamlined monograph-update mechanism, which it used to clear bemotrizinol in June 2026 — the first addition since the late 1990s.
What makes bemotrizinol better than existing US filters?
Its standout trait is strong standalone UVA coverage (peaking near 340 nm) without a white cast. The US has no requirement that UVA protection reach a fraction of labeled SPF, unlike the EU's one-third rule, so American formulas have historically lagged on UVA defense — the wavelength tied to photoaging and skin-cancer risk.
Is bemotrizinol safe?
The FDA deemed it generally recognized as safe and effective for adults and children 6 months and older at up to 6% concentration, based on studies of 500+ patients showing no irritation or allergic reactions and minimal skin absorption — plasma levels rarely exceeded the FDA's 0.5 ng/mL threshold.
When can I buy sunscreen with bemotrizinol?
The first US products reached shelves the week of October 14, 2026, led by Ultra Violette, which plans a second formula for January 2027. More brands are expected to launch BEMT formulas heading into summer 2027.
Sources
- Orbit Post, October 15, 2026 — "First New Sunscreen in 25 Years Reaches US Store Shelves" — AP's October 14 shelf-arrival reporting, 25-year gap, first UVA+UVB standalone chemical filter in the US, OTC-drug explanation for the gap, more brands into summer 2027.
- WebProNews, October 15, 2026 — "America's Sunscreen Gap Closes: Bemotrizinol Finally Reaches U.S. Shelves" — monograph finalized June 9, 2026; 500+ patient safety studies; GRASE for 6 months and older; Yale dermatologist Christopher Bunick on low skin penetration.
- Badiyaa, October 16, 2026 — "US gets its first new sunscreen filter since the 1990s" — first new active ingredient since late 1990s; cleared up to 6%; Ultra Violette first US seller; second formula January 2027; EU use since 2000.
- DrugTopics, August 2026 — "FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products" — CARES Act monograph pathway; acting FDA director Mike Davis quote; HHS Secretary Robert F. Kennedy Jr. statement tying approval to the MAHA Strategy Report.
- The Plain Record, September 5, 2026 — 27-year gap framing; Stanford dermatologist Susan Swetter on the UVA gap and ~80% skin-cancer risk reduction from regular early-life sunscreen use; Swiss development in the 1990s; cleared for children 6 months and older.
Comments
Post a Comment